The University of Chicago Header Logo

Connection

Russell D. Cohen to Colitis, Ulcerative

Back to Details
This is a "connection" page, showing publications Russell D. Cohen has written about Colitis, Ulcerative.
Russell D. Cohen
Connection Strength
9.974
Colitis, Ulcerative
  1. Looking from the Past to the Future: How Janus Kinase Inhibitors Have Altered the Therapy of Ulcerative Colitis. Dig Dis Sci. 2023 06; 68(6):2248-2251.
    View in: PubMed
    Score: 0.559
  2. Rare and Well Done: Endoscopic Control of Colonic Hemorrhage in Severe Ulcerative Colitis. Dig Dis Sci. 2022 03; 67(3):805-809.
    View in: PubMed
    Score: 0.518
  3. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data. J Crohns Colitis. 2020 Feb 10; 14(2):192-204.
    View in: PubMed
    Score: 0.449
  4. Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis. Inflamm Bowel Dis. 2015 Jul; 21(7):1719-36.
    View in: PubMed
    Score: 0.326
  5. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ. 2015 Jun; 18(6):447-56.
    View in: PubMed
    Score: 0.320
  6. Dietary fiber intake and Crohn's disease. Gastroenterology. 2014 Apr; 146(4):1133.
    View in: PubMed
    Score: 0.297
  7. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol. 2012 Sep 24; 12:132.
    View in: PubMed
    Score: 0.269
  8. Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. Drug Des Devel Ther. 2011 Feb 27; 5:111-6.
    View in: PubMed
    Score: 0.241
  9. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010 Apr; 31(7):693-707.
    View in: PubMed
    Score: 0.223
  10. How should we treat severe acute steroid-refractory ulcerative colitis? Inflamm Bowel Dis. 2009 Jan; 15(1):150-1.
    View in: PubMed
    Score: 0.208
  11. What is the optimal maintenance treatment for ulcerative colitis? Inflamm Bowel Dis. 2008 Oct; 14 Suppl 2:S236-7.
    View in: PubMed
    Score: 0.204
  12. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis. 2008 Jun; 14(6):738-43.
    View in: PubMed
    Score: 0.200
  13. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther. 2007 Nov 01; 26(9):1179-86.
    View in: PubMed
    Score: 0.192
  14. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006 Oct; 12(10):979-94.
    View in: PubMed
    Score: 0.178
  15. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006 Aug 01; 24(3):465-74.
    View in: PubMed
    Score: 0.176
  16. MLN-02 in IBD: is "super-selective" really super? Gastroenterology. 2006 May; 130(6):1923-4.
    View in: PubMed
    Score: 0.173
  17. Azathioprine versus mesalamine in steroid-dependent ulcerative colitis: long-awaited results? Gastroenterology. 2006 Feb; 130(2):607-8; discussion 608.
    View in: PubMed
    Score: 0.170
  18. Postoperative management of ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2005 Dec; 7(6):492-9.
    View in: PubMed
    Score: 0.168
  19. Medical therapy for ulcerative colitis: the state of the art and beyond. Curr Gastroenterol Rep. 2004 Dec; 6(6):488-95.
    View in: PubMed
    Score: 0.157
  20. Medical management of severe ulcerative colitis. Gastroenterol Clin North Am. 2004 Jun; 33(2):235-50, viii.
    View in: PubMed
    Score: 0.151
  21. Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
    View in: PubMed
    Score: 0.146
  22. Infliximab in ulcerative colitis: is there a placebo (effect) in the house? Gastroenterology. 2003 Jun; 124(7):1990-1; discussion 1991.
    View in: PubMed
    Score: 0.141
  23. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 07; 21(7):1913-1923.e2.
    View in: PubMed
    Score: 0.139
  24. The mesalamine wars heat up-enter balsalazide. Gastroenterology. 2003 Feb; 124(2):574-5.
    View in: PubMed
    Score: 0.138
  25. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep. 2002 Dec; 4(6):497-505.
    View in: PubMed
    Score: 0.136
  26. Endo-histologic Normalization Is Achievable with Tofacitinib and Is Associated with Improved Clinical Outcomes. Dig Dis Sci. 2023 04; 68(4):1464-1472.
    View in: PubMed
    Score: 0.135
  27. Outcomes of Ileoanal Pouch Anastomosis in Pediatric Ulcerative Colitis Are Worse in the Modern Era: A Time Trend Analysis Outcomes Following Ileal Pouch-Anal Anastomosis in Pediatric Ulcerative Colitis. Inflamm Bowel Dis. 2022 09 01; 28(9):1386-1394.
    View in: PubMed
    Score: 0.134
  28. Serum Cytomegalovirus Polymerase Chain Reaction Test Is a Valuable Negative Predictor of Infection in Acute Severe Ulcerative Colitis. Dig Dis Sci. 2023 03; 68(3):897-901.
    View in: PubMed
    Score: 0.133
  29. Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2023 08; 21(9):2407-2409.e2.
    View in: PubMed
    Score: 0.130
  30. Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. Dig Dis Sci. 2022 08; 67(8):4020-4031.
    View in: PubMed
    Score: 0.130
  31. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis. Dig Dis. 2022; 40(5):553-564.
    View in: PubMed
    Score: 0.127
  32. Evolving medical therapies for ulcerative colitis. Curr Gastroenterol Rep. 2001 Dec; 3(6):464-70.
    View in: PubMed
    Score: 0.127
  33. Inpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis. Inflamm Bowel Dis. 2021 10 18; 27(10):1620-1625.
    View in: PubMed
    Score: 0.126
  34. Intravenous cyclosporine in severe ulcerative colitis: ready to stand alone? Gastroenterology. 2001 May; 120(6):1541-3.
    View in: PubMed
    Score: 0.122
  35. Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes. Clin Gastroenterol Hepatol. 2022 02; 20(2):293-302.e9.
    View in: PubMed
    Score: 0.120
  36. Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 01 19; 27(2):236-241.
    View in: PubMed
    Score: 0.120
  37. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021 03; 160(4):1131-1139.
    View in: PubMed
    Score: 0.119
  38. Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated With Good Maternal and Fetal Outcomes. Clin Gastroenterol Hepatol. 2021 11; 19(11):2444-2446.e2.
    View in: PubMed
    Score: 0.118
  39. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
    View in: PubMed
    Score: 0.116
  40. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000 May; 95(5):1263-76.
    View in: PubMed
    Score: 0.114
  41. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020 03; 51(6):637-643.
    View in: PubMed
    Score: 0.111
  42. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis. 2019 Sep 19; 13(9):1105-1110.
    View in: PubMed
    Score: 0.109
  43. Follow-Up of Patients With Ulcerative Colitis and Histological Normalization. Clin Gastroenterol Hepatol. 2020 04; 18(4):987-988.e1.
    View in: PubMed
    Score: 0.107
  44. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 12; 64(12):3596-3601.
    View in: PubMed
    Score: 0.107
  45. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol. 1999 Jun; 94(6):1587-92.
    View in: PubMed
    Score: 0.107
  46. Abnormal Pouchogram Predicts Pouch Failure Even in Asymptomatic Patients. Dis Colon Rectum. 2019 04; 62(4):463-469.
    View in: PubMed
    Score: 0.106
  47. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
    View in: PubMed
    Score: 0.105
  48. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis. 1999 Feb; 5(1):1-10.
    View in: PubMed
    Score: 0.105
  49. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
    View in: PubMed
    Score: 0.100
  50. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis. 2018 05 18; 24(6):1291-1297.
    View in: PubMed
    Score: 0.100
  51. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
    View in: PubMed
    Score: 0.098
  52. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. Dig Dis Sci. 2018 May; 63(5):1294-1301.
    View in: PubMed
    Score: 0.098
  53. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.097
  54. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791.
    View in: PubMed
    Score: 0.094
  55. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20.
    View in: PubMed
    Score: 0.087
  56. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.085
  57. Surveillance colonoscopy in ulcerative colitis: is the message loud and clear? Am J Gastroenterol. 1995 Dec; 90(12):2090-2.
    View in: PubMed
    Score: 0.084
  58. Ulcerative Colitis Care Pathway. Gastroenterology. 2015 Jul; 149(1):238-45.
    View in: PubMed
    Score: 0.081
  59. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1601-8.e1-4.
    View in: PubMed
    Score: 0.071
  60. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm. 2012 Nov-Dec; 18(9):701-12.
    View in: PubMed
    Score: 0.068
  61. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.
    View in: PubMed
    Score: 0.054
  62. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc. 2007 Jun; 65(7):998-1004.
    View in: PubMed
    Score: 0.046
  63. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis. 2006 Oct; 12(10):972-8.
    View in: PubMed
    Score: 0.044
  64. Quality of life after proctocolectomy with ileoanal anastomosis for patients with ulcerative colitis. J Clin Gastroenterol. 2006 Sep; 40(8):669-77.
    View in: PubMed
    Score: 0.044
  65. First two patients with ulcerative colitis who developed classical thrombotic thrombocytopenic purpura successfully treated with medical therapy and plasma exchange. J Clin Apher. 2002; 17(4):204-6.
    View in: PubMed
    Score: 0.032
  66. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001 Oct; 96(10):2929-33.
    View in: PubMed
    Score: 0.031
  67. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.027
  68. Protection from primary sclerosing cholangitis: smoke trails of just coattails? Gastroenterology. 1996 May; 110(5):1658-62.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.